A New Treatment for Severe Pancreatitis
One Health Advancement of RABI-767 for the Management of Acute Pancreatitis
This work explores a new medicine, RABI-767, to help manage severe acute pancreatitis in both people and animals.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Lamassu Pharma INC. NIH-funded |
| Lab location | 1 site (Durham, UNITED STATES) |
| Project ID | NIH-11124672 on NIH RePORTER |
What this research studies
Acute pancreatitis can become very serious, leading to organ failure, and currently, there isn't an effective treatment. This project focuses on a new medicine called RABI-767, which aims to stop the harmful processes that turn mild pancreatitis into a severe condition. Researchers believe that by blocking certain enzymes, RABI-767 can prevent organ damage and widespread inflammation. The initial phase involves a trial in dogs with spontaneous acute pancreatitis to understand how the medicine works and find the best way to give it. The information gathered from these studies will then help design future human clinical trials.
Who could benefit from this research
Good fit: This research is foundational for patients who experience acute pancreatitis, especially those at risk of developing severe forms of the condition.
Not a fit: Patients with other conditions not related to acute pancreatitis would not directly benefit from this specific treatment.
Why it matters
Potential benefit: If successful, this new medicine could offer the first effective treatment for severe acute pancreatitis, potentially preventing organ failure and improving patient outcomes.
How similar studies have performed: This approach builds on existing clinical and preclinical data, and prior work has shown that inhibiting certain enzymes can reduce organ failure in animal models of severe acute pancreatitis.
Where this research is happening
Durham, UNITED STATES
- Lamassu Pharma INC. — Durham, United States (Active)
Researchers
- Principal investigator: Hanna, Gabi — Lamassu Pharma INC.
- Study coordinator: Hanna, Gabi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.